Molecular analysis of ciprofloxacin resistance and clonal relatedness of clinical Escherichia coli isolates from haematology patients receiving ciprofloxacin prophylaxis

Journal of Antimicrobial Chemotherapy

Volumn 66, Issue 8, 2011, Pages 1739-1744

  van Hees, Babette C ^a,b   Tersmette, Matthijs ^a   Willems, Rob J L ^b   de Jong, Ben ^a   Biesma, Douwe ^a,b   van Hannen, Erik J ^a  

^a ST ANTONIUS HOSPITAL   (Netherlands)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

AFLP; DGGE; GyrA

Indexed keywords

CIPROFLOXACIN; DNA TOPOISOMERASE (ATP HYDROLYSING) A;

AMPLIFIED FRAGMENT LENGTH POLYMORPHISM; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL STRAIN; BACTERIUM ISOLATE; CLONAL VARIATION; CONTROLLED STUDY; DENATURING GRADIENT GEL ELECTROPHORESIS; ESCHERICHIA COLI; GENE MUTATION; GENETIC ANALYSIS; HUMAN; MAJOR CLINICAL STUDY; MOLECULAR EVOLUTION; NEUTROPENIA; NONHUMAN; PROPHYLAXIS; SINGLE ENZYME AMPLIFIED FRAGMENT LENGTH POLYMORPHISM;

ANTI-BACTERIAL AGENTS; ANTIBIOTIC PROPHYLAXIS; CIPROFLOXACIN; CLUSTER ANALYSIS; DENATURING GRADIENT GEL ELECTROPHORESIS; DNA GYRASE; DNA, BACTERIAL; DRUG RESISTANCE, BACTERIAL; ESCHERICHIA COLI; ESCHERICHIA COLI INFECTIONS; GENOTYPE; HEMATOLOGIC NEOPLASMS; HUMANS; MOLECULAR EPIDEMIOLOGY; MOLECULAR TYPING; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH;

EID: 79960440336     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkr216     Document Type: Article

References (31)

1. Blanco JE, Blanco M, Mora A et al. Prevalence of bacterial resistance to quinolones and other antimicrobials among avian Escherichia coli strains isolated from septicemic and healthy chickens in Spain. J Clin Microbiol 1997; 35: 2184-5.
2. Cometta A, Calandra T, Bille J et al. Escherichia coli resistant to fluoroquinolones in patients with cancer and neutropenia. N Engl J Med 1994; 330: 1240-1.
3. Ena J, Lopez-Perezagua MM, Martinez-Peinado C et al. Emergence of ciprofloxacin resistance in Escherichia coli isolates after widespread use of fluoroquinolones. Diagn Microbiol Infect Dis 1998; 30: 103-7.
4. Garau J, Xercavins M, Rodriguez-Carballeira M et al. Emergence and dissemination of quinolone-resistant Escherichia coli in the community. Antimicrob Agents Chemother 1999; 43: 2736-41.
5. Lautenbach E, Strom BL, Nachamkin I et al. Longitudinal trends in fluoroquinolone resistance among Enterobacteriaceae isolates from inpatients and outpatients, 1989-2000: differences in the emergence and epidemiology of resistance across organisms. Clin Infect Dis 2004; 38: 655-62.
6. Richard P, Delangle MH, Raffi F et al. Impact of fluoroquinolone administration on the emergence of fluoroquinolone-resistant gram-negative bacilli from gastrointestinal flora. Clin Infect Dis 2001; 32: 162-6.
7. Lautenbach E, Metlay JP, Bilker WB et al. Association between fluoroquinolone resistance and mortality in Escherichia coli and Klebsiella pneumoniae infections: the role of inadequate empirical antimicrobial therapy. Clin Infect Dis 2005; 41: 923-9.
8. Jacoby GA. Mechanisms of resistance to quinolones. Clin Infect Dis 2005; 41 Suppl 2: S120-6.
9. Hopkins KL, Davies RH, Threlfall EJ. Mechanisms of quinolone resistance in Escherichia coli and Salmonella: recent developments. Int J Antimicrob Agents 2005; 25: 358-73.
10. Lautenbach E, Fishman NO, Metlay JP et al. Phenotypic and genotypic characterization of fecal Escherichia coli isolates with decreased susceptibility to fluoroquinolones: results from a large hospital-based surveillance initiative. J Infect Dis 2006; 194: 79-85.
11. Oethinger M, Jellen-Ritter AS, Conrad S et al. Colonization and infection with fluoroquinolone-resistant Escherichia coli among cancer patients: clonal analysis. Infection 1998; 26: 379-84.
12. Baum HV, Franz U, Geiss HK. Prevalence of ciprofloxacin-resistant Escherichia coli in hematologic-oncologic patients. Infection 2000; 28: 278-81.
13. Kern WV, Klose K, Jellen-Ritter AS et al. Fluoroquinolone resistance of Escherichia coli at a cancer center: epidemiologic evolution and effects of discontinuing prophylactic fluoroquinolone use in neutropenic patients with leukemia. Eur J Clin Microbiol Infect Dis 2005; 24: 111-8.
14. Perea S, Hidalgo M, Arcediano A et al. Incidence and clinical impact of fluoroquinolone-resistant Escherichia coli in the faecal flora of cancer patients treated with high dose chemotherapy and ciprofloxacin prophylaxis. J Antimicrob Chemother 1999; 44: 117-20.
15. Carratala J, Fernandez-Sevilla A, Tubau F et al. Emergence of fluoroquinolone-resistant Escherichia coli in fecal flora of cancer patients receiving norfloxacin prophylaxis. Antimicrob Agents Chemother 1996; 40: 503-5.
16. Cattaneo C, Quaresmini G, Casari S et al. Recent changes in bacterial epidemiology and the emergence of fluoroquinolone-resistant Escherichia coli among patients with haematological malignancies: results of a prospective study on 823 patients at a single institution. J Antimicrob Chemother 2008; 61: 721-8.
17. Oethinger M, Conrad S, Kaifel K et al. Molecular epidemiology of fluoroquinolone-resistant Escherichia coli bloodstream isolates from patients admitted to European cancer centers. Antimicrob Agents Chemother 1996; 40: 387-92.
18. Herpers BL, Immink MM, de Jong BA et al. Coding and non-coding polymorphisms in the lectin pathway activator L-ficolin gene in 188 Dutch blood bank donors. Mol Immunol 2006; 43: 851-5.
19. Conrad S, Oethinger M, Kaifel K et al. gyrA mutations in high-level fluoroquinolone-resistant clinical isolates of Escherichia coli. J Antimicrob Chemother 1996; 38: 443-55.
20. Heisig P, Schedletzky H, Falkenstein-Paul H. Mutations in the gyrA gene of a highly fluoroquinolone-resistant clinical isolate of Escherichia coli. Antimicrob Agents Chemother 1993; 37: 696-701.
21. Oram M, Fisher LM. 4-Quinolone resistance mutations in the DNA gyrase of Escherichia coli clinical isolates identified by using the polymerase chain reaction. Antimicrob Agents Chemother 1991; 35: 387-9.
22. Ouabdesselam S, Hooper DC, Tankovic J et al. Detection of gyrA and gyrB mutations in quinolone-resistant clinical isolates of Escherichia coli by single-strand conformational polymorphism analysis and determination of levels of resistance conferred by two different single gyrA mutations. Antimicrob Agents Chemother 1995; 39: 1667-70.
23. Komp LP, Karlsson A, Hughes D. Mutation rate and evolution of fluoroquinolone resistance in Escherichia coli isolates from patients with urinary tract infections. Antimicrob Agents Chemother 2003; 47: 3222-32.
24. Belkum A, Goessens W, van der Schee C et al. Rapid emergence of ciprofloxacin-resistant enterobacteriaceae containing multiple gentamicin resistance-associated integrons in a Dutch hospital. Emerg Infect Dis 2001; 7: 862-71.
25. Tascini C, Menichetti F, Bozza S et al. Molecular typing of fluoroquinolone-resistant and fluoroquinolone-susceptible Escherichia coli isolated from blood of neutropenic cancer patients in a single center. Clin Microbiol Infect 1999; 5: 457-61.
26. Gafter-Gvili A, Paul M, Fraser A et al. Effect of quinolone prophylaxis in afebrile neutropenic patients on microbial resistance: systematic review and meta-analysis. J Antimicrob Chemother 2007; 59: 5-22.
27. Gafter-Gvili A, Paul M, Fraser A et al. Antibiotic prophylaxis in neutropenic patients. Isr Med Assoc J 2007; 9: 460-2.
28. Hammond SP, Baden LR. Antibiotic prophylaxis during chemotherapy-induced neutropenia for patients with acute leukemia. Curr Hematol Malig Rep 2007; 2: 97-103.
29. Mebis J, Goossens H, Berneman ZN. Antibiotic management of febrile neutropenia: current developments and future directions. J Chemother 2010; 22: 5-12.
30. Pascoe J, Steven N. Antibiotics for the prevention of febrile neutropenia. Curr Opin Hematol 2009; 16: 48-52.
31. Schlesinger A, Paul M, Gafter-Gvili A et al. Infection-control interventions for cancer patients after chemotherapy: a systematic review and meta-analysis. Lancet Infect Dis 2009; 9: 97-107.